 | |
 | |
| Clinical data | |
|---|---|
| Routes of administration | Oral |
| ATC code | |
| Pharmacokinetic data | |
| Protein binding | 69% |
| Metabolism | Hepatic |
| Elimination half-life | 3 to 8 hours |
| Identifiers | |
| |
| CAS Number |
|
| PubChem CID | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| KEGG |
|
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C14H16N2Na2O6S3 |
| Molar mass | 450.45 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
Sulfoxoneoraldesulfone sodium is an anti-leprosy drug.[1] It is also known as diasone. Sulfoxone sodium was introduced in Japan in 1948.[2] Ernest Muir introduced it to Western use while serving as superintendent of the Chacachacare LeprosariumonTrinidad in the Caribbean.[3]
|
| |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Nucleic acid inhibitor |
| ||||||||
| Protein synthesis inhibitor |
| ||||||||
| Cell envelope antibiotic |
| ||||||||
| Other/unknown |
| ||||||||
| Combinations |
| ||||||||
| |||||||||
|
| |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Antifolates (inhibit bacterial purine metabolism, thereby inhibiting DNA and RNA synthesis) |
| ||||||||||||||||
| Quinolones (inhibit bacterial topoisomerase and/or DNA gyrase, thereby inhibiting DNA replication) |
| ||||||||||||||||
| Anaerobic DNA inhibitors |
| ||||||||||||||||
| RNA synthesis |
| ||||||||||||||||
| |||||||||||||||||
